Category: BIIB – Biogen Inc. Common Stock

Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.

Natalizumab Equally Safe, Effective on 6-Week Dosing Schedule Vs 4-Week Schedule in Multiple Sclerosis  Pharmacy Times

1. Biogen/Eisai push for second approval in Alzheimer’s disease  PMLiVE
2. Patients Want Biogen Alzheimer’s Drug Aduhelm, Will Insurance Pay?  Bloomberg
3. Why I Sold My Biogen Stock  Motley Fool
4. Watchdog will review FDA approval of Biogen’s Alzheimer’s drug  STAT
5. Biogen, Eisai to push for fast FDA approval for Alzheimer’s drug – Boston Business Journal  Boston Business Journal
6. View Full coverage on Google News

1. Why I Sold My Biogen Stock  Nasdaq
2. Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM  GlobeNewswire
3. Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer’s drug  CNBC
4. Biogen’s aducanumab crosses FDA finish line just in time to save its business  FiercePharma
5. Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense  The New York Times
6. View Full Coverage on Google News

Since getting clearance from the U.S. Food and Drug Administration (FDA) for its Alzheimer’s drug, Aduhelm, on June 7, Biogen (NASDAQ: BIIB) has continued to face an ever-intensifying whirlwind of controversy. In my view, the company’s future prospects of making winning drugs for intractable neurological illnesses had become tainted to the point where holding it was a liability. Given the exceptional circumstances of Biogen’s saga with Aduhelm and its rapidly weakening stock performance, I thought it was time to hit the road.

1. Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in  GlobeNewswire
2. Biogen Inc. (BIIB) Releases Study Results Evaluating Different Natalizumab Dosage Schedules in Treating Relapsing-Remitting Multiple Sclerosis  InvestorsObserver
3. Biogen highlights results from late-stage natalizumab multiple sclerosis study  Seeking Alpha
4. Biogen (BIIB) Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting MS  StreetInsider.com
5. View Full Coverage on Google News

1. Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in  GlobeNewswire
2. Biogen Inc. (BIIB) Releases Study Results Evaluating Different Natalizumab Dosage Schedules in Treating Relapsing-Remitting Multiple Sclerosis  InvestorsObserver
3. Biogen highlights results from late-stage natalizumab multiple sclerosis study  Seeking Alpha
4. Biogen (BIIB) Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting MS  StreetInsider.com
5. View Full coverage on Google News

1. Biogen Alzheimer’s Drug Approval to Get Inspector’s Probe  Bloomberg
2. Watchdog will review FDA approval of Biogen’s Alzheimer’s drug  STAT
3. Biogen, Eisai to push for fast FDA approval for Alzheimer’s drug – Boston Business Journal  Boston Business Journal
4. HHS OIG will review FDA’s approval of Biogen’s aducanumab  Mass Device
5. Federal investigators to review FDA’s ‘accelerated pathway’ over Alzheimer’s drug approval  Reuters
6. View Full Coverage on Google News